Tillkännagivande • Jul 28
Link Pharma Chem Limited to Report Q1, 2027 Results on Aug 05, 2026 Link Pharma Chem Limited announced that they will report Q1, 2027 results on Aug 05, 2026 Reported Earnings • Jul 28
Full year 2026 earnings released: EPS: ₹0.17 (vs ₹2.31 loss in FY 2025) Full year 2026 results: EPS: ₹0.17 (up from ₹2.31 loss in FY 2025). Revenue: ₹274.3m (up 7.9% from FY 2025). Net income: ₹769.0k (up ₹11.0m from FY 2025). Profit margin: 0.3% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Tillkännagivande • Jul 27
Link Pharma Chem Limited, Annual General Meeting, Aug 20, 2026 Link Pharma Chem Limited, Annual General Meeting, Aug 20, 2026, at 11:30 Indian Standard Time. Reported Earnings • May 23
Full year 2026 earnings released: EPS: ₹0.17 (vs ₹2.31 loss in FY 2025) Full year 2026 results: EPS: ₹0.17 (up from ₹2.31 loss in FY 2025). Revenue: ₹276.3m (up 8.7% from FY 2025). Net income: ₹769.0k (up ₹11.0m from FY 2025). Profit margin: 0.3% (up from net loss in FY 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Tillkännagivande • May 14
Link Pharma Chem Limited to Report Q4, 2026 Results on May 21, 2026 Link Pharma Chem Limited announced that they will report Q4, 2026 results on May 21, 2026 Valuation Update With 7 Day Price Move • Mar 16
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹23.40, the stock trades at a trailing P/E ratio of 76.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 39% over the past three years. Recent Insider Transactions • Mar 15
Whole-Time Chairman recently bought ₹1.0m worth of stock On the 13th of March, Satish Thakur bought around 41k shares on-market at roughly ₹25.21 per share. This transaction amounted to 4.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Satish's only on-market trade for the last 12 months. Reported Earnings • Feb 16
Third quarter 2026 earnings released: EPS: ₹0.15 (vs ₹1.50 loss in 3Q 2025) Third quarter 2026 results: EPS: ₹0.15 (up from ₹1.50 loss in 3Q 2025). Revenue: ₹65.3m (up 22% from 3Q 2025). Net income: ₹682.0k (up ₹7.35m from 3Q 2025). Profit margin: 1.0% (up from net loss in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Tillkännagivande • Feb 07
Link Pharma Chem Limited to Report Q3, 2026 Results on Feb 14, 2026 Link Pharma Chem Limited announced that they will report Q3, 2026 results at 9:15 AM, Indian Standard Time on Feb 14, 2026 New Risk • Jan 28
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (15% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.7% average weekly change). Earnings have declined by 52% per year over the past 5 years. Market cap is less than US$10m (₹126.3m market cap, or US$1.37m). Minor Risk Revenue is less than US$5m (₹259m revenue, or US$2.8m). Reported Earnings • Nov 15
Second quarter 2026 earnings released: EPS: ₹0.03 (vs ₹0.69 loss in 2Q 2025) Second quarter 2026 results: EPS: ₹0.03 (up from ₹0.69 loss in 2Q 2025). Revenue: ₹63.4m (up 32% from 2Q 2025). Net income: ₹156.0k (up ₹3.22m from 2Q 2025). Profit margin: 0.2% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Tillkännagivande • Nov 08
Link Pharma Chem Limited to Report Q2, 2026 Results on Nov 13, 2025 Link Pharma Chem Limited announced that they will report Q2, 2026 results on Nov 13, 2025 New Risk • Oct 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.3% average weekly change). Earnings have declined by 50% per year over the past 5 years. Market cap is less than US$10m (₹154.3m market cap, or US$1.74m). Minor Risks High level of debt (45% net debt to equity). Revenue is less than US$5m (₹244m revenue, or US$2.7m). Tillkännagivande • Aug 13
Link Pharma Chem Limited, Annual General Meeting, Sep 09, 2025 Link Pharma Chem Limited, Annual General Meeting, Sep 09, 2025, at 11:30 Indian Standard Time. Reported Earnings • Aug 02
First quarter 2026 earnings released: EPS: ₹0.91 (vs ₹0.67 in 1Q 2025) First quarter 2026 results: EPS: ₹0.91 (up from ₹0.67 in 1Q 2025). Revenue: ₹80.2m (down 9.3% from 1Q 2025). Net income: ₹4.02m (up 36% from 1Q 2025). Profit margin: 5.0% (up from 3.4% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance. Tillkännagivande • Jul 24
Link Pharma Chem Limited to Report Q1, 2026 Results on Aug 01, 2025 Link Pharma Chem Limited announced that they will report Q1, 2026 results on Aug 01, 2025 New Risk • Jun 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 46% per year over the past 5 years. Market cap is less than US$10m (₹168.7m market cap, or US$1.97m). Minor Risks High level of debt (45% net debt to equity). Share price has been volatile over the past 3 months (7.6% average weekly change). Revenue is less than US$5m (₹254m revenue, or US$3.0m). Reported Earnings • May 28
Full year 2025 earnings released: ₹2.31 loss per share (vs ₹3.07 loss in FY 2024) Full year 2025 results: ₹2.31 loss per share (improved from ₹3.07 loss in FY 2024). Revenue: ₹256.2m (down 14% from FY 2024). Net loss: ₹10.3m (loss narrowed 25% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance. Tillkännagivande • May 19
Link Pharma Chem Limited to Report Q4, 2025 Results on May 27, 2025 Link Pharma Chem Limited announced that they will report Q4, 2025 results on May 27, 2025 New Risk • Apr 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Earnings have declined by 38% per year over the past 5 years. Market cap is less than US$10m (₹159.0m market cap, or US$1.87m). Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Revenue is less than US$5m (₹270m revenue, or US$3.2m). Reported Earnings • Feb 08
Third quarter 2025 earnings released: ₹1.50 loss per share (vs ₹0.50 profit in 3Q 2024) Third quarter 2025 results: ₹1.50 loss per share (down from ₹0.50 profit in 3Q 2024). Revenue: ₹47.8m (down 40% from 3Q 2024). Net loss: ₹6.67m (down 402% from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance. Tillkännagivande • Jan 28
Link Pharma Chem Limited to Report Q3, 2025 Results on Feb 07, 2025 Link Pharma Chem Limited announced that they will report Q3, 2025 results on Feb 07, 2025 Reported Earnings • Nov 13
Second quarter 2025 earnings released: ₹0.69 loss per share (vs ₹2.30 loss in 2Q 2024) Second quarter 2025 results: ₹0.69 loss per share (improved from ₹2.30 loss in 2Q 2024). Revenue: ₹51.6m (down 14% from 2Q 2024). Net loss: ₹3.06m (loss narrowed 70% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance. Tillkännagivande • Oct 31
Link Pharma Chem Limited to Report Q2, 2025 Results on Nov 11, 2024 Link Pharma Chem Limited announced that they will report Q2, 2025 results on Nov 11, 2024 Tillkännagivande • Oct 06
Link Pharma Chem Limited Announces Cessation of Directors Link Pharma Chem Limited informed that Mr. Suresh Balram Dhatrak (DIN: 00365256) and Mr. Devang Uttamchand Shah (DIN: 00704950), Independent directors have completed their tenure of 10 years i.e second term on 26th September, 2024 and consequently ceased to be an Independent Directors of the Company w.e.f. close of business hours on 26th September, 2024. Tillkännagivande • Sep 05
Link Pharma Chem Limited, Annual General Meeting, Sep 27, 2024 Link Pharma Chem Limited, Annual General Meeting, Sep 27, 2024, at 11:30 Indian Standard Time. Reported Earnings • Aug 10
First quarter 2025 earnings released: EPS: ₹0.67 (vs ₹1.85 loss in 1Q 2024) First quarter 2025 results: EPS: ₹0.67 (up from ₹1.85 loss in 1Q 2024). Revenue: ₹91.2m (up 16% from 1Q 2024). Net income: ₹2.96m (up ₹11.2m from 1Q 2024). Profit margin: 3.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 97 percentage points per year, which is a significant difference in performance. Tillkännagivande • Aug 02
Link Pharma Chem Limited to Report Q1, 2025 Results on Aug 09, 2024 Link Pharma Chem Limited announced that they will report Q1, 2025 results on Aug 09, 2024 Reported Earnings • Jun 04
Full year 2024 earnings released: ₹3.07 loss per share (vs ₹1.47 profit in FY 2023) Full year 2024 results: ₹3.07 loss per share (down from ₹1.47 profit in FY 2023). Revenue: ₹305.4m (down 21% from FY 2023). Net loss: ₹13.6m (down 308% from profit in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance. Tillkännagivande • May 23
Link Pharma Chem Limited to Report Q4, 2024 Results on May 29, 2024 Link Pharma Chem Limited announced that they will report Q4, 2024 results on May 29, 2024 Reported Earnings • Feb 11
Third quarter 2024 earnings released: EPS: ₹0.50 (vs ₹0.40 in 3Q 2023) Third quarter 2024 results: EPS: ₹0.50 (up from ₹0.40 in 3Q 2023). Revenue: ₹83.1m (down 11% from 3Q 2023). Net income: ₹2.21m (up 23% from 3Q 2023). Profit margin: 2.7% (up from 1.9% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance. Tillkännagivande • Feb 01
Link Pharma Chem Limited to Report Q3, 2024 Results on Feb 09, 2024 Link Pharma Chem Limited announced that they will report Q3, 2024 results on Feb 09, 2024 Reported Earnings • Nov 10
Second quarter 2024 earnings released: ₹2.30 loss per share (vs ₹2.16 profit in 2Q 2023) Second quarter 2024 results: ₹2.30 loss per share (down from ₹2.16 profit in 2Q 2023). Revenue: ₹60.2m (down 29% from 2Q 2023). Net loss: ₹10.2m (down 206% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings. Tillkännagivande • Nov 09
Link Pharma Chem Limited Announces CFO Changes Link Pharma Chem Limited informed that Mr. Sanjib Dutta has appointed as Chief Financial Officer (KMP) of the Company with effect from 08th November, 2023 at the meeting of Board of Directors held on 8th November, 2023. Mr. Sanjib Dutta is Commerce Graduate from Calcutta University, and having 27 Years of Work-Experience in Company Accounts, Banking, Goods and Services Tax, Commercial Part & Statutory Compliances etc. Board Change • Nov 07
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Rachna Ghai was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Tillkännagivande • Nov 01
Link Pharma Chem Limited Announces Resignation of Mr. Jayesh Pushpavadan Jani as Chief Financial Officer Link Pharma Chem Limited announced that Mr. Jayesh Pushpavadan Jani has tendered his resignation from the post of Chief Financial Officer (KMP) of the Company with effect from 31st October, 2023 (closing business hours) due to almost attaining the age of retirement. Tillkännagivande • Aug 29
Link Pharma Chem Limited, Annual General Meeting, Sep 21, 2023 Link Pharma Chem Limited, Annual General Meeting, Sep 21, 2023, at 11:30 Indian Standard Time. Agenda: To consider and adopt the Audited Financial Statements for the Financial Year ended March 31, 2023 and the Reports of the Board of Directors and Auditors thereon; to appoint a director in place of Mr. Rishikesh Thakur, who retires by rotation and, being eligible, offers himself for re-appointment; to consider appointment of Mr. Satish G. Thakur as a Chairman & Whole-time Director; and to consider other matters. Tillkännagivande • Aug 06
Link Pharma Chem Limited to Report Q1, 2024 Results on Aug 14, 2023 Link Pharma Chem Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Tillkännagivande • Jul 12
Link Pharma Chem Limited Announces Disruption in Operation at Nandesari Plant of the Company Due to Closure Notice from Gujarat Pollution Control Board Link Pharma Chem Limited has received notice from the Gujarat Pollution Control Board, Gandhinagar effecting closure of operations of its plant situated at Nandesari, Dist. Vadodara. Gujarat Pollution Control Board (GPCB) has laid certain conditions and has asked the Company to fulfil the same. The Company after analyzing order has started taking effective steps as directed by the GPCB to seek relief against the order. Reported Earnings • May 31
Full year 2023 earnings released: EPS: ₹1.47 (vs ₹4.24 in FY 2022) Full year 2023 results: EPS: ₹1.47 (down from ₹4.24 in FY 2022). Revenue: ₹386.1m (down 28% from FY 2022). Net income: ₹6.54m (down 65% from FY 2022). Profit margin: 1.7% (down from 3.5% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • May 20
Link Pharma Chem Limited to Report Q4, 2023 Results on May 29, 2023 Link Pharma Chem Limited announced that they will report Q4, 2023 results on May 29, 2023 Reported Earnings • Feb 12
Third quarter 2023 earnings released: EPS: ₹0.40 (vs ₹1.58 in 3Q 2022) Third quarter 2023 results: EPS: ₹0.40 (down from ₹1.58 in 3Q 2022). Revenue: ₹93.6m (down 33% from 3Q 2022). Net income: ₹1.79m (down 75% from 3Q 2022). Profit margin: 1.9% (down from 5.0% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Feb 03
Link Pharma Chem Limited to Report Q3, 2023 Results on Feb 09, 2023 Link Pharma Chem Limited announced that they will report Q3, 2023 results on Feb 09, 2023 Valuation Update With 7 Day Price Move • Jan 27
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to ₹56.95, the stock trades at a trailing P/E ratio of 15.4x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 307% over the past three years. Valuation Update With 7 Day Price Move • Jan 10
Investor sentiment improved over the past week After last week's 18% share price gain to ₹67.20, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 444% over the past three years. Valuation Update With 7 Day Price Move • Dec 23
Investor sentiment improved over the past week After last week's 19% share price gain to ₹48.45, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 294% over the past three years. Reported Earnings • Nov 20
Second quarter 2023 earnings released: EPS: ₹2.16 (vs ₹0.94 in 2Q 2022) Second quarter 2023 results: EPS: ₹2.16 (up from ₹0.94 in 2Q 2022). Revenue: ₹90.8m (down 39% from 2Q 2022). Net income: ₹9.61m (up 130% from 2Q 2022). Profit margin: 11% (up from 2.8% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment improved over the past week After last week's 25% share price gain to ₹49.60, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 272% over the past three years. Tillkännagivande • Nov 06
Link Pharma Chem Limited to Report Q2, 2023 Results on Nov 14, 2022 Link Pharma Chem Limited announced that they will report Q2, 2023 results on Nov 14, 2022 Tillkännagivande • Sep 17
Link Pharma Chem Limited Announces Executive Changes The board of directors of Link Pharma Chem Limited in its meeting held on September 16, 2022, approved the Resignation Letter from Mr. Bhushan Ravindra Joshi (Membership No.: A40085) from the post of Company Secretary & Compliance Officer of the Company effective from closure of business hours on September 17, 2022. Appointment of Ms. Khushbu Prakashbhai Patel (Membership No.: A65182) as Company Secretary and Compliance Office of the Company effective from September 19, 2022, under Section 203 of Companies Act, 2013 and under Regulation 6 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and Regulation 9(3) of SEBI (Prohibition of Insider Trading) Regulations, 2015. Brief profile of Khushbu Prakashbhai Patel: Ms. Khushbu Prakashbhai Patel is an Associate Member of the Institute of Company Secretaries of India having Membership No. A65182. She is also Master in Commerce, Bachelors in Law and Bachelors of Business Administration and having experience of Corporate Laws, Listing Regulations etc. Reported Earnings • Aug 18
First quarter 2023 earnings released: ₹0.66 loss per share (vs ₹1.10 profit in 1Q 2022) First quarter 2023 results: ₹0.66 loss per share (down from ₹1.10 profit in 1Q 2022). Revenue: ₹108.2m (down 19% from 1Q 2022). Net loss: ₹2.93m (down 160% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 49% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jul 14
Full year 2022 earnings released: EPS: ₹4.24 (vs ₹2.44 in FY 2021) Full year 2022 results: EPS: ₹4.24 (up from ₹2.44 in FY 2021). Revenue: ₹535.6m (up 54% from FY 2021). Net income: ₹18.8m (up 74% from FY 2021). Profit margin: 3.5% (up from 3.1% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Jul 12
Link Pharma Chem Limited, Annual General Meeting, Aug 05, 2022 Link Pharma Chem Limited, Annual General Meeting, Aug 05, 2022, at 11:00 Indian Standard Time. Agenda: To consider and adopt the Audited Financial Statements for the Financial Year ended March 31, 2022 and the Reports of the Board of Directors and Auditors thereon; to appoint a Director in place of Mr. Satish Thakur, (DIN: 00292129) who retires by rotation and, being eligible, offers himself for re-appointment; and to consider appointment of Statutory Auditors of the Company. Reported Earnings • Jun 03
Full year 2022 earnings released: EPS: ₹4.24 (vs ₹2.44 in FY 2021) Full year 2022 results: EPS: ₹4.24 (up from ₹2.44 in FY 2021). Revenue: ₹540.3m (up 55% from FY 2021). Net income: ₹18.8m (up 74% from FY 2021). Profit margin: 3.5% (up from 3.1% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth. Tillkännagivande • May 21
Link Pharma Chem Limited to Report Q4, 2022 Results on May 30, 2022 Link Pharma Chem Limited announced that they will report Q4, 2022 results on May 30, 2022 Valuation Update With 7 Day Price Move • May 10
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₹41.85, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 109% over the past three years. Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improved over the past week After last week's 15% share price gain to ₹42.90, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 87% over the past three years. Valuation Update With 7 Day Price Move • Feb 21
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹40.75, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 102% over the past three years. Tillkännagivande • Feb 15
Link Pharma Chem Limited Announces Appointment of Jayesh Pushpavadan Jani as Chief Financial Officer, Effective February 15, 2022 Link Pharma Chem Limited announced that Mr. Jayesh Pushpavadan Jani has appointed as Chief Financial Officer (KMP) of the Company from the start of business hours on 15th February, 2022. Reported Earnings • Feb 15
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹1.58 (up from ₹0.76 in 3Q 2021). Revenue: ₹143.5m (up 45% from 3Q 2021). Net income: ₹7.02m (up 109% from 3Q 2021). Profit margin: 4.9% (up from 3.4% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 30% per year whereas the company’s share price has increased by 29% per year. Valuation Update With 7 Day Price Move • Dec 23
Investor sentiment improved over the past week After last week's 20% share price gain to ₹40.85, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 59% over the past three years. Reported Earnings • Aug 04
Full year 2021 earnings released: EPS ₹2.44 (vs ₹2.14 in FY 2020) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: ₹348.1m (up 37% from FY 2020). Net income: ₹10.8m (up 14% from FY 2020). Profit margin: 3.1% (down from 3.7% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Jun 05
Investor sentiment improved over the past week After last week's 16% share price gain to ₹37.45, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 23% over the past three years. Reported Earnings • May 30
Full year 2021 earnings released: EPS ₹2.44 (vs ₹2.14 in FY 2020) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: ₹348.3m (up 37% from FY 2020). Net income: ₹10.8m (up 14% from FY 2020). Profit margin: 3.1% (down from 3.7% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has remained flat. Valuation Update With 7 Day Price Move • Apr 24
Investor sentiment improved over the past week After last week's 44% share price gain to ₹36.00, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 17x in the Chemicals industry in India. Total loss to shareholders of 17% over the past three years. Reported Earnings • Feb 17
Third quarter 2021 earnings released: EPS ₹0.76 (vs ₹0.79 in 3Q 2020) The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₹99.1m (up 35% from 3Q 2020). Net income: ₹3.37m (down 4.5% from 3Q 2020). Profit margin: 3.4% (down from 4.8% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 12% per year. Tillkännagivande • Feb 04
Link Pharma Chem Limited to Report Q3, 2021 Results on Feb 12, 2021 Link Pharma Chem Limited announced that they will report Q3, 2021 results on Feb 12, 2021 Valuation Update With 7 Day Price Move • Jan 29
Investor sentiment improved over the past week After last week's 17% share price gain to ₹26.50, the stock is trading at a trailing P/E ratio of 9.5x, up from the previous P/E ratio of 8.1x. This compares to an average P/E of 18x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 30%. Is New 90 Day High Low • Jan 27
New 90-day low: ₹20.10 The company is down 9.0% from its price of ₹22.10 on 29 October 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 17% over the same period. Is New 90 Day High Low • Dec 16
New 90-day high: ₹26.65 The company is up 17% from its price of ₹22.80 on 17 September 2020. The Indian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment improved over the past week After last week's 18% share price gain to ₹26.65, the stock is trading at a trailing P/E ratio of 9.6x, up from the previous P/E ratio of 8.1x. This compares to an average P/E of 18x in the Chemicals industry in India. Total returns to shareholders over the past three years are 33%. Reported Earnings • Nov 13
Second quarter 2021 earnings released: EPS ₹0.60 The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹85.6m (up 27% from 2Q 2020). Net income: ₹2.67m (up 406% from 2Q 2020). Profit margin: 3.1% (up from 0.8% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Nov 10
New 90-day high: ₹25.00 The company is up 34% from its price of ₹18.60 on 12 August 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. Is New 90 Day High Low • Oct 06
New 90-day high: ₹24.95 The company is up 73% from its price of ₹14.40 on 08 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. Tillkännagivande • Sep 26
Link Pharma Chem Limited Appoints Rishikesh Thakur as Managing Director Link Pharma Chem Limited announced that Mr. Rishikesh Thakur has been appointed as Managing Director of the Company for period of three years with effect from September 24, 2020.